The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.r Pulmonary nodulosis

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.x Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.ab Delayed ILD, -pneumonitis, -fibrosis

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.ab Cough (lone)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.a Angioedema (may cause UAO, asphyxia and death)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.ak Endobronchial lymphoproliferative disorder

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.b Eosinophilic pleural effusion

VI. Pleural and/or pericardial involvement

VI.e Hemothorax - Serosanguineous pleural effusion

VI. Pleural and/or pericardial involvement

VI.i Pleuritis (can cause chest pain)

VI. Pleural and/or pericardial involvement

VI.n Hemopericardium - Bloody pericardial effusion

VI. Pleural and/or pericardial involvement

VI.t Serositis - Polyserositis

VII. Pulmonary vasculopathy

VII.a Pulmonary embolism - Venous thrombosis/thromboembolism

VIII. Mediastinal involvement

VIII.a Lymphadenopathy (intrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.a DRES syndrome - DRESS-like reaction

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.m Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.w Multiple organ dysfunction/failure (MODS/MOF)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.c Pleuritic chest pain

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.w Imaging: Lung nodule or nodules

XVI. Imaging

XVI.be Imaging: Intrathoracic lymph node enlargement

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.b BAL: An excess proportion of neutrophils

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.c BAL: An excess proportion of eosinophils

XIX. Pathology

XIX.a Path: NSIP-cellular pattern (see also Ia, Ib)

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.f Path: ILD with a granulomatous component (see also Im)

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

XIX. Pathology

XIX.t Path: Pulmonary edema (see also II/IIa)

XIX. Pathology

XIX.v Path: NSIP-fibrotic pattern

XIX. Pathology

XIX.ck Path: Lymphoproliferative disease, endothoracic

XX. Infections & related conditions

XX.b Opportunistic pulmonary/systemic infections

XX. Infections & related conditions

XX.d Pneumocystis jiroveci pulmonary colonization

XX. Infections & related conditions

XX.e Pneumocystis jiroveci pneumonia

XX. Infections & related conditions

XX.h Nontuberculous pulmonary mycobacterial infection/superinfection

XX. Infections & related conditions

XX.q Viral pneumonia

XXI. Neoplastic conditions

XXI.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)

XXI. Neoplastic conditions

XXI.g Lymphomatoid granulomatosis (pulmonary, endothoracic)

XXI. Neoplastic conditions

XXI.k Lymphoproliferative disease (extrathoracic)